ScholarIQanswers from OpenAlex & ORCID
Robert G. Maki
ResearcherPublications, citations & collaboration network
Robert G. Maki is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Robert G. Maki have?
ScholarIQindexed works
Robert G. Maki has 763 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Robert G. Maki have?
ScholarIQcitation count
Robert G. Maki has 53,621 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Robert G. Maki?
ScholarIQh-index
Robert G. Maki has an h-index of 108 in OpenAlex.
What is the i10-index of Robert G. Maki?
ScholarIQi10-index
Robert G. Maki has an i10-index of 311 in OpenAlex.
What is the ORCID of Robert G. Maki?
ScholarIQorcid
The ORCID for Robert G. Maki is on the source record.
What is the OpenAlex record for Robert G. Maki?
ScholarIQopenalex
The OpenAlex for Robert G. Maki is on the source record.
What are the most-cited papers on Robert G. Maki?
ScholarIQmost cited works
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Eunice L. Kwak, Yung‐Jue Bang, D. Ross Camidge, Alice T. Shaw, Benjamin Solomon, Robert G. Maki, Sai‐Hong Ignatius Ou, Bruce J. Dezube, Pasi A. Jänne, Daniel B. Costa, Marileila Varella‐Garcia, Woo Ho Kim, Thomas J. Lynch, Panos Fidias, Hannah Stubbs, Jeffrey A. Engelman, Lecia V. Sequist, Weiwei Tan, Leena Gandhi, Mari Mino–Kenudson, Greg C. G. Wei, S. Martin Shreeve, Mark J. Ratain, Jeffrey Settleman, James G. Christensen, Daniel A. Haber, Keith D. Wilner, Ravi Salgia, Geoffrey I. Shapiro, Jeffrey W. Clark, A. John Iafrate
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
Hussein A. Tawbi, Melissa Burgess, Vanessa Bolejack, Brian A. Van Tine, Scott M. Schuetze, James Hu, Sandra P. D’Angelo, Steven Attia, Richard F. Riedel, Dennis A. Priebat, Sujana Movva, Lara E. Davis, Scott H. Okuno, Damon R. Reed, John Crowley, Lisa H. Butterfield, Ruth Salazar, Jaime Rodriguez‐Canales, Alexander J. Lazar, Ignacio I. Wistuba, Laurence H. Baker, Robert G. Maki, Denise K. Reinke, Shreyaskumar Patel
NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
George D. Demetri, Margaret von Mehren, Cristina R. Antonescu, Ronald P. DeMatteo, Kristen N. Ganjoo, Robert G. Maki, Peter W. T. Pisters, Chandrajit P. Raut, Richard F. Riedel, Scott M. Schuetze, Hema Sundar, Jonathan C. Trent, Jeffrey D. Wayne
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
Alice T. Shaw, Beow Y. Yeap, Benjamin Solomon, Gregory J. Riely, Justin F. Gainor, Jeffrey A. Engelman, Geoffrey I. Shapiro, Daniel B. Costa, Sai‐Hong Ignatius Ou, Mohit Butaney, Ravi Salgia, Robert G. Maki, Marileila Varella‐Garcia, Robert C. Doebele, Yung‐Jue Bang, Kimary Kulig, Paulina Selaru, Yiyun Tang, Keith D. Wilner, Eunice L. Kwak, Jeffrey W. Clark, A. John Iafrate, D. Ross Camidge
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial
George D. Demetri, Margaret von Mehren, Robin L. Jones, Martee L. Hensley, Scott M. Schuetze, Arthur P. Staddon, Mohammed Milhem, A. Elias, Kristen N. Ganjoo, Hussein A. Tawbi, Brian Andrew Van Tine, Alexander I. Spira, Andrew Dean, Nushmia Z. Khokhar, Youn Choi Park, Roland E. Knoblauch, Trilok Parekh, Robert G. Maki, Shreyaskumar Patel